Skip to content
DataLookout
Menu

NCT07934069

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of BON-107 in Healthy Participants

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of Participants with Adverse Events
Timeframe: From first dose to 30 days after the last dose of study drug; up to approximately 40 days.
Number of Participants with Clinically Significant Change from Baseline in Clinical Laboratory Tests
Timeframe: From first dose to up to 30 days after the last dose of study drug; up to approximately 40 days.
Number of Participants with Clinically Significant Change from Baseline in Vital Signs
Timeframe: From first dose to up to 30 days after the last dose of study drug; up to approximately 40 days.
Number of Participants with Clinically Significant Change from Baseline in Electrocardiogram Cardiac Conduction Intervals
Timeframe: From first dose to up to 30 days after the last dose of study drug; up to approximately 40 days.

Secondary (17)

Parts A and B: Area Under the Concentration Time Curve (AUC) from Time Zero to Last Quantifiable Time (AUClast) of BON-107
Parts A and B: AUC from Time Zero to Infinite Time (AUCinf) of BON-107
Parts A and B: AUC from Time Zero to End of Dosing Interval (AUCtau) of BON-107
Parts A and B: Maximum Observed Plasma Concentration (Cmax) of BON-107
Parts A and B: Time to Maximum Plasma Concentration (Tmax) of BON-107
Show 12 moreShow less
Parts A and B: Trough Plasma Concentration (Ctrough) of BON-107
Parts A and B: Terminal Half-Life (t1/2) of BON-107
Parts A and B: Apparent Drug Clearance (CL/F) of BON-107
Parts A and B: Apparent Volume of Distribution (Vz/F) of BON-107
Part C: AUC from Time Zero to 24 Hours Postdose (AUC0-24) of BON-107
Part C: AUClast of BON-107
Part C: AUCinf of BON-107
Part C: Cmax of BON-107
Part C: Tmax of BON-107
Part C: t1/2 of BON-107
Part C: CL/F of BON-107
Part C: Vz/F of BON-107

Arms and interventions

Part A: Single Ascending Doses (SAD) of BON-107Experimental

Sequential cohorts of healthy participants will receive a single dose of BON-107 at increasing dose levels.

Part A: PlaceboPlacebo comparator

Sequential cohorts of healthy participants will receive a single dose of matching placebo.

Part B: Multiple Ascending Doses (MAD) of BON-107Experimental

Sequential cohorts of healthy participants will receive multiple doses of BON-107 at increasing dose levels.

Part B: PlaceboPlacebo comparator

Sequential cohorts of healthy participants will receive multiple doses of matching placebo.

Part C: Food Effect of BON-107Experimental

Healthy participants will take BON-107 in a fed and fasted state, with a washout period between.

Drugs: BON-107, Placebo